181 related articles for article (PubMed ID: 10641699)
1. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group.
Koman LA; Mooney JF; Smith BP; Walker F; Leon JM
J Pediatr Orthop; 2000; 20(1):108-15. PubMed ID: 10641699
[TBL] [Abstract][Full Text] [Related]
2. Splint: the efficacy of orthotic management in rest to prevent equinus in children with cerebral palsy, a randomised controlled trial.
Maas JC; Dallmeijer AJ; Huijing PA; Brunstrom-Hernandez JE; van Kampen PJ; Jaspers RT; Becher JG
BMC Pediatr; 2012 Mar; 12():38. PubMed ID: 22448907
[TBL] [Abstract][Full Text] [Related]
3. New clinical and research trends in lower extremity management for ambulatory children with cerebral palsy.
Damiano DL; Alter KE; Chambers H
Phys Med Rehabil Clin N Am; 2009 Aug; 20(3):469-91. PubMed ID: 19643348
[TBL] [Abstract][Full Text] [Related]
4. Prediction Model for Identifying Computational Phenotypes of Children with Cerebral Palsy Needing Neurotoxin Treatments.
Bertoncelli CM; Latalski M; Bertoncelli D; Bagui S; Bagui SC; Gautier D; Solla F
Toxins (Basel); 2022 Dec; 15(1):. PubMed ID: 36668840
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial.
Koman LA; Brashear A; Rosenfeld S; Chambers H; Russman B; Rang M; Root L; Ferrari E; Garcia de Yebenes Prous J; Smith BP; Turkel C; Walcott JM; Molloy PT
Pediatrics; 2001 Nov; 108(5):1062-71. PubMed ID: 11694682
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin in the management of the lower limb in cerebral palsy.
Cosgrove AP; Corry IS; Graham HK
Dev Med Child Neurol; 1994 May; 36(5):386-96. PubMed ID: 8168657
[TBL] [Abstract][Full Text] [Related]
7. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial.
Kim K; Shin HI; Kwon BS; Kim SJ; Jung IY; Bang MS
Dev Med Child Neurol; 2011 Mar; 53(3):239-44. PubMed ID: 21087238
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy.
Kay RM; Rethlefsen SA; Fern-Buneo A; Wren TA; Skaggs DL
J Bone Joint Surg Am; 2004 Nov; 86(11):2377-84. PubMed ID: 15523006
[TBL] [Abstract][Full Text] [Related]
9. Upper extremity spasticity in children with cerebral palsy: a randomized, double-blind, placebo-controlled study of the short-term outcomes of treatment with botulinum A toxin.
Koman LA; Smith BP; Williams R; Richardson R; Naughton M; Griffin L; Evans P
J Hand Surg Am; 2013 Mar; 38(3):435-46.e1. PubMed ID: 23428186
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation.
Bjornson K; Hays R; Graubert C; Price R; Won F; McLaughlin JF; Cohen M
Pediatrics; 2007 Jul; 120(1):49-58. PubMed ID: 17606561
[TBL] [Abstract][Full Text] [Related]
11. Effects of botulinum toxin A in ambulant adults with spastic cerebral palsy: a randomized double-blind placebo controlled-trial.
Maanum G; Jahnsen R; Stanghelle JK; Sandvik L; Keller A
J Rehabil Med; 2011 Mar; 43(4):338-47. PubMed ID: 21305227
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement.
Love SC; Novak I; Kentish M; Desloovere K; Heinen F; Molenaers G; O'Flaherty S; Graham HK;
Eur J Neurol; 2010 Aug; 17 Suppl 2():9-37. PubMed ID: 20633177
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence.
Lukban MB; Rosales RL; Dressler D
J Neural Transm (Vienna); 2009 Mar; 116(3):319-31. PubMed ID: 19142573
[TBL] [Abstract][Full Text] [Related]
14. Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study.
Mall V; Heinen F; Siebel A; Bertram C; Hafkemeyer U; Wissel J; Berweck S; Haverkamp F; Nass G; Döderlein L; Breitbach-Faller N; Schulte-Mattler W; Korinthenberg R
Dev Med Child Neurol; 2006 Jan; 48(1):10-3. PubMed ID: 16359588
[TBL] [Abstract][Full Text] [Related]
15. The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial.
Love SC; Valentine JP; Blair EM; Price CJ; Cole JH; Chauvel PJ
Eur J Neurol; 2001 Nov; 8 Suppl 5():50-8. PubMed ID: 11851734
[TBL] [Abstract][Full Text] [Related]
16. Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review.
Boyd RN; Hays RM
Eur J Neurol; 2001 Nov; 8 Suppl 5():1-20. PubMed ID: 11851730
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy.
Ade-Hall RA; Moore AP
Cochrane Database Syst Rev; 2000; (2):CD001408. PubMed ID: 10796784
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of incobotulinum toxin A [Xeomin(®)] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial.
Carraro E; Trevisi E; Martinuzzi A
Eur J Paediatr Neurol; 2016 Jul; 20(4):532-7. PubMed ID: 27177451
[TBL] [Abstract][Full Text] [Related]
19. Effect of multilevel botulinum toxin a and comprehensive rehabilitation on gait in cerebral palsy.
Scholtes VA; Dallmeijer AJ; Knol DL; Speth LA; Maathuis CG; Jongerius PH; Becher JG
Pediatr Neurol; 2007 Jan; 36(1):30-9. PubMed ID: 17162194
[TBL] [Abstract][Full Text] [Related]
20. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial.
Koman LA; Mooney JF; Smith BP; Goodman A; Mulvaney T
J Pediatr Orthop; 1994; 14(3):299-303. PubMed ID: 8006158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
